4-oxo-fenretinide, administered alone and in combination...

Details 4-oxo-fenretinide, administered alone and in combination... 4-oxo-fenretinide, administered alone and in combination...

2007-01-30

2007-01-30

Kumar, Shailendra (Department: 1621)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Radical -xh acid, or anhydride, acid halide or salt thereof...

C554S065000, C564S161000, C514S617000

Reexamination Certificate

active

10557311

ABSTRACT:
A drug based on a metabolite of fenretinide, or N-(4hydroxyphenyl) retinamide (4-HPR), specifically 4-oxo-N-(4-hydroxyphenyl) retinamide (4-oxo-4-HPR), is used in the treatment of different kinds of tumors, in particular in the treatment of ovarian carcinoma, breast tumor and neuroblastoma. The drug is more potent than fenretinide alone, and enhances the effects of fenretinide when administered together with fenretinide.

REFERENCES:
patent: 6696606 (2004-02-01), Curley et al.
Ulukaya E et al. “Fenretinide and its relation to cancer” Cancer Treatment Reviews, Saunders, US, vol. 25, No. 4, Aug. 1999, pp. 229-235, XP008009394 ISSN: 0305-7372.
Mehta R R et al.: “Metabolism of N-(4-hydroxpheny) retinamide (4-HPR) to N-(4-methyoxphenyl) retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells” European Journal of Cancer, vol. 34, No. 6, May 1998, pp. 902-907, XP002303841 ISSN: 0959-8049 abstract.
Apprierto V et al.: “Decrease in drug accumulation and in tumor aggressiveness marker expression in a fenretinide-induced resistant ovarian tumor cell line.” British Journal of Cancer. Jun. 1, 2001, vol. 84, No. 11, Jun. 1, 2001, pp. 1528-1534, XP002303842 ISSN: 0007-0920 abstract p. 1528, left-hand column.
Ozols Robert F et al.: “Specific keynote: Chemoprevention of ovarian cancer: The journey begins.” Gynecologic Oncology, vol. 88, No. 1 Part 2, Jan. 2003, pp. S59-S66, XP002303843 ISSN: 0090-8258 p. S62, last paragraph-p. S63, paragraph 1.
Ribatti Domenico et al.: “Fenretinide as an anti-angiogenic agent in neuroblastoma.” Cancer Letters, vol. 197, No. 1-2, Jul. 18, 2003, pp. 181-184, XP002303844 ISSN: 0304-3835 abstract.

Affiliated with

Also associated with

Rating

4-oxo-fenretinide, administered alone and in combination... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-oxo-fenretinide, administered alone and in combination..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-oxo-fenretinide, administered alone and in combination... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3823723